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Abstract  
Background: The efficacy of systemic antineoplastic therapy on recurrent WHO II and III 
meningiomas is unclear. 
Methods: We performed a retrospective multicenter analysis of serial cranial magnetic 
resonance images (MRI) in patients with recurrent WHO II and III meningiomas treated with 
antineoplastic systemic therapies. Growth rates for tumor volume and diameter, as well as 
change rates for edema size were calculated for all lesions. 
Results: We identified a total of 34 patients (23 atypical, 11 anaplastic meningiomas) with a 
total of 57 meningioma lesions that had been treated at six European institutions. Systemic 
therapies included bevacizumab, cytotoxic chemotherapy, somatostatin analogues, tyrosine 
kinase inhibitors. Overall, tumor growth rates decreased during systemic therapy by 51% for 
tumor diameter and 14% for tumor volume growth rates compared to the period before 
initiation of systemic therapy. The most pronounced decrease in meningioma growth rates 
during systemic therapy was evident in patients treated with bevacizumab with a reduction of 
80% in diameter and 59% in volume growth. Furthermore, a decrease in size of peritumoral 
edema after initiation of systemic therapy was exclusively observed in patients treated with 
bevacizumab (-107%).  
Conclusions: Our data indicate that systemic therapy may inhibit growth of recurrent WHO 
II and III meningiomas to some extent. In our small cohort bevacizumab had the most 
pronounced inhibitory effect on tumor growth and in addition some anti-edematous activity. 
Prospective studies are needed to better define the role of medical therapies in this tumor type. 
Key words: Atypical meningioma, anaplastic meningioma, chemotherapy, bevacizumab, 
anti-angiogenesis
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INTRODUCTION   
Meningiomas are the most frequent primary intracranial tumors in adults according to local 
and international brain tumor registries with an incidence rate of about 30% with a female 
predominance, followed by glioblastoma and pituitary adenoma.1,2 Based on the WHO 
classification, meningiomas are histopathologically classified and graded into three different 
subgroups: benign meningiomas (WHO I), atypical meningiomas (WHO II) and anaplastic or 
malignant meningiomas (WHO III).3 The majority of these subgroups are benign 
meningiomas, followed by atypical (up to 20% of all meningiomas) and anaplastic (about 1-
3% of all meningiomas) meningiomas.1  
While benign meningiomas are usually curable by surgery, atypical and anaplastic 
meningiomas are characterized by aggressive behavior and a high recurrence rate.3 No 
accepted therapy standard exists for meningiomas after exhaustion of surgical and 
radiotherapeutic options. A variety systemic antineoplastic therapy including hydroxyurea, 
temozolomide, irinotecan, interferon-alpha, mifepristone, octreotide analogues, megestrol 
acetate, bevacizumab, imatinib, erlotinib, and gefitinib have been investigated in small studies 
and are being used in the clinical setting.4-13 However, the validity of the available studies is 
limited by small sample sizes, retrospective study designs, heterogeneous patient populations, 
lack of control arms and varying response criteria, thus rendering the benefit of these drugs 
unclear.14 
In the present study, we aimed to analyze the growth rates of recurrent WHO II and III 
meningiomas before, during and after treatment with systemic agents in order to provide 
novel information on the effect of drug treatment on the disease course.  
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MATERIAL AND METHODS 
Patients 
Institutional review board approval for this retrospective European multicenter study was 
obtained from each participating institution. All participating institutions were asked to 
provide radiological as well as predefined epidemiological and clinical data of the patients 
using a prepared form (see Supplement 1).  
The inclusion criteria were as follows: (1) patient has histological diagnosis of WHO grade II 
or grade III meningioma according to 2007 WHO criteria; (2) patient has received systemic 
antineoplastic therapy for tumor recurrence after previous operation and/or radiotherapy; (3) 
availability of digital data sets of multiple MR examinations taken before, during and after the 
administration of systemic antineoplastic therapy.   
Patient recruitment per institution was as follows: institution 1 (Vienna, n = 14), institution 2 
(Leuven, n = 5), institution 3 (Lille, n=4), institution 4 (Zurich, n=4), institution 5 (Aarau, 
n=4) and institution 6 (Essen, n=3). First radiological diagnosis of meningioma was made 
between December 2002 and December 2013 and systemic antineoplastic therapy 
commenced between October 2005 and October 2013.  
Image acquisition 
All patients received an MRI examination with a routine clinical imaging protocol of the 
brain. In total 224 MRI examinations were included. The mean duration between two MRI 
examinations was 116 days (standard deviation (SD) 88 days). Each MRI examination 
included at least one T1-weighted sequence without and with contrast enhancement. In 
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addition, a T2-weighted sequence was performed in 90.6% of all MRI examinations (203 out 
of 224 MRI examinations).  
Image analysis 
The anonymized radiological data for participating patients from all institutions were 
collected in form of digital data. The MR images were qualitatively evaluated at institution 1 
on a PACS (Picture Archiving and Communication System, Centricity, GE Healthcare) 
workstation by an experienced neuroradiologist (J.F.) regarding their usability for further 
postprocessing.  Image postprocessing was performed using an open-source software 
(MRIcron).15 Maximum tumor diameter, tumor volume and the volume of peritumoral edema 
were measured for each of the 224 MRI examinations by the same neuroradiologist (J.F.), 
blinded to all clinical patient data. T1-weighted post-contrast images were selected to 
determine the maximum tumor diameter as well as the tumor volume. The T2-weighted 
images were used to depict tumor edema. Maximum tumor diameter was defined as the 
biggest diameter of the contrast-enhanced tumor area measured in axial, coronal or sagittal 
image dimension. Tumor volume was automatically calculated on the basis of multiple 
manually defined regions of interests (ROI) including the whole contrast enhancing tumor 
area as well as cystic parts of the tumor in the T1-weighted post contrast sequences. 
Analogous to the tumor volume, peritumoral edema was determined using multiple ROI 
including the peritumoral hyperintense signal alterations in T2-weighted images, excluding 
contrast-enhancing tumor areas. 
Statistical analysis 
Resulting measurements from tumor volume, maximum tumor diameter, and the volume of 
peritumoral edema were submitted for further analysis. All lesions were subdivided into 3 
different subgroups related to patient`s therapy status. The subgroup “pre-therapeutic” 
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represents all meningiomas before systemic therapy, the subgroup “therapeutic” included a 
pre-therapeutic baseline measurement within 4 weeks before the start of systemic therapy, all 
measurements during systemic therapy and the first measurement after systemic therapy if it 
was performed within 4 weeks after the completion of systemic therapy. All measurements 
after the systemic therapy are summarized in the “post-therapeutic” subgroup. 
Measurements of maximum tumor diameter, maximum tumor volume and maximum 
peritumoral edema volume of every lesion were used to derive gradients of decrease and 
increase, which were specified as average growth rates for tumor volume and diameter and 
average change rates for edemas throughout the manuscript. Growth and change rates were 
defined as the decrease or increase in tumor diameter, tumor volume or peritumoral edema 
volume over a period of time (t), expressed as cm/t and cm3/t, respectively. The time period 
was determined by the average MR follow-up interval of the lesions.  Pearson correlation 
coefficient was used to assess the relation between the calculated growth rates of tumor 
diameter and tumor volume.  
A positive growth rate indicated an increase of tumor diameter, tumor volume or edema 
volume, while a negative growth rate reflected a decrease of the different measurements. A 
growth rate of zero indicated no change in volume or diameter, respectively.   
Statistical Package for the Social Sciences (SPSS, Chicago, Illinois, MI, USA), version 20.0 
was used for descriptive statistics of the cohorts. Visualizations were performed in MATLAB 
(Matlab 7.14.0, Release 2012a, Mathworks Inc., Sherborn, MA, USA). Testing for group 
differences between therapies was not utilized because of the small and unbalanced sample 
size.  
 
N-O-D-15-00252R1	 8
 
RESULTS 
Patient characteristics 
We identified 34 patients with a total of 57 meningioma lesions that had been treated in six 
European institutions. Twenty-three patients (68%) had atypical meningiomas and 11 patients 
(32%) had anaplastic meningiomas. Systemic therapies included bevacizumab (n=5), 
cytotoxic chemotherapy (n= 9), somatostatin analogues (n=9), tyrosine kinase inhibitors 
(n=7). In 4 patients radiological data during systemic therapy were not available, therefore 
these patients were only included in the “pre-therapeutic” subgroup. Detailed patient´s 
baseline characteristics and the types of administered systemic therapies are given in 
Supplement 2 and Supplement 3.  
Thirty-two meningiomas were analyzable in the “pre-therapeutic” time window, 37 
meningiomas in the “therapeutic” time window, and 26 in the “post-therapeutic” time 
window. The mean time period was 140 days (SD = 124 days, range = 13 – 637 days; mean 
number of MR examinations = 3.65, range = 2 - 6) for all pre-therapeutic MR examinations, 
78 days (SD = 23 days, range = 41 - 156 days; mean number of MR examination = 3.13, 
range = 2 - 7) during systemic therapy and 142 days (SD = 79 days, range = 21 – 334 days; 
mean number of MR examination = 3.92, range = 2 - 7) for all post-therapeutic MR 
examinations. 
 
Analysis of solid tumor lesions 
Measurements of maximum tumor diameter and tumor volume were represented as average 
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growth rates, and further subdivided in “pre-therapeutic” lesion (n=32), “therapeutic” lesion 
(n=37) and “post-therapeutic” lesion (n=26) values. Overall, diameter and volume growth rate 
values of the tumor lesions showed a high correlation in total (Pearson correlation coefficient 
r=0.722; p= 1.4903*10^-16), in the pre-therapeutic (r= 0.794; p=5.8995*10^-8), therapeutic 
(r=0.52; p= 0.001), and post-therapeutic (r=0.892; p=9.144*10^-10) subgroups.  
Table 1 and Figures 1A, 1B and 2A, 2B detail the tumor growth rates per time window and 
type of administered therapy. Overall, the mean tumor growth rates decreased by 51% for 
tumor diameter and 14% for tumor volume in the “therapeutic” period compared to the “pre-
therapeutic” period. Comparing the growth rates between the different therapy types, we 
observed the highest decrease of growth rate from the “pre-therapeutic” to the “therapeutic” 
period in patients treated with bevacizumab (diameter: -80%, volume: -59%), followed by the 
subgroup of patients treated with chemotherapy (diameter: -54%, volume: +7%) and tyrosine 
kinase inhibitors (diameter: -40%, volume: -29%). Interestingly, in the post-therapeutic period 
patients treated with bevacizumab showed the highest increase with 200% in growth rates 
with regard to tumorous lesion diameter and the second highest increase in terms of tumor 
volume with 50% in comparison to the “therapeutic” period. The lowest growth rates in the 
post-therapeutic period were observed with tyrosine kinase inhibitors, both with regard to 
tumor diameter and tumor volume.  
Furthermore, tumor growth rates were subdivided, regarding tumor histology, into tumor 
diameter and volume growth rates of WHO grade II meningiomas and WHO grade III 
meningiomas per time window in Table 2. In the “pre-therapeutic” as well as “therapeutic” 
period tumor growth rates (both diameter and volume) of the different histological 
meningioma subtypes were approximately balanced, whereas in the “post-therapeutic” period 
tumor growth rates were considerably lower in atypical meningiomas than in anaplastic 
meningiomas. 
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A further analysis using RECIST-criteria during treatment with systemic therapy 
(“therapeutic” period) revealed stable disease (defined as ≤ 30% decrease or ≥ 20% increase 
in the maximum tumor diameter) in 25 patients and progressive disease (defined as ≥ 20% 
increase in the maximum tumor diameter) in 12 cases as the best responses during the 
treatment periods (see Supplement 4). 
 
Analysis of peritumoral edema 
Changes of peritumoral edema were defined as the change rates of maximum peritumoral 
edema volume over a period of time and were evaluated during the “pre-therapeutic” period 
in 12 meningiomas, during the “therapeutic” period in 36 meningiomas and during the “post-
therapeutic” period in 25 meningiomas. In the overall cohort, mean change rates of 
peritumoral edema volume were positive in all time periods and were highest in the “pre-
therapeutic” and lowest in the “post-therapeutic” period (Table 3, Figure 1C). Comparing 
edema volume change rates between the patient populations treated with different therapies, a 
decrease in edema volume was evident exclusively in the “therapeutic” period in patients 
treated with bevacizumab with a change rate of -0,007 cm3/t (SD=0.0210) (resulting in a 
reduction of peritumoral edema change rate of 107% compared to the “pre-therapeutic” 
period), whereas all other included therapies together showed an average increase in 
peritumoral edema change rate of 0,1070 cm3/t (SD=0.2350) (resulting in an increase of 
peritumoral edema change rate of 7% compared to the “pre-therapeutic” period). The 
remarkable effect of bevacizumab on peritumoral edema change rates during the therapy 
period in comparison to all other included systemic therapies is visualized in Figure 2C.  
A reduction in peritumoral edema volume change rate by 29% compared to the “pre-
therapeutic” period was detected during the application of chemotherapy, while in case of 
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somatostatin analogues and tyrosine kinase inhibitors peritumoral edema showed an increase 
in the peritumoral edema change rates with 95% and 15% respectively. After the termination 
of systemic therapy no change of peritumoral edema volume was determined in the 
“chemotherapy” subgroup. The second lowest peritumoral edema change rate after 
termination of systemic therapy was determined in the “bevacizumab” cohort, whereas 
patients who were treated with somatostatin analogues or tyrosine kinase inhibitor showed the 
highest post-therapeutic peritumoral edema change rates. 
Moreover, peritumoral edema change rates were evaluated with regard to the different 
histological meningioma subgroups in Table 2. Remarkably, peritumoral edema volume 
change rates were lower in atypical meningiomas in the “pre-therapeutic” as well as in the 
“therapeutic” period than in anaplastic meningiomas, while there was almost no difference in 
the “post-therapeutic” period. Moreover, during systemic therapy atypical meningiomas 
showed increased peritumoral edema change rates while the peritumoral edema in anaplastic 
meningiomas decreased in comparison to the “pre-therapeutic” period. After systemic therapy 
peritumoral edema volumes showed the lowest change rates in atypical as well as anaplastic 
meningiomas in comparison to the “pre-therapeutic” and “therapeutic” period. 
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DISCUSSION 
The role of systemic therapies in recurrent WHO II and III meningiomas is ill defined. So far, 
medical therapy of these tumors has only been evaluated in case reports, retrospective patient 
series and small and uncontrolled prospective studies. The 6 month progression free survival 
(PFS-6) rates reported among these studies show a high variability and range from 3% to 
64.3%. A recent systematic analysis proposed a PFS-6 rate of 26% as benchmark for 
historical comparisons.14 Considering this benchmark, hydroxyurea, octreotide analogues, 
gefitinib and erlotinib were deemed ineffective 4,13,16 while antiangiogenic drugs including 
bevacizumab, vatalanib and sunitinib showed potential activity with PFS-6 rates of 37.5% to 
64.3%.11,14,17,18,19 Interestingly, our data support a potential role of anti-angiogenic treatment 
in recurrent WHO II and III meningioma, as the most pronounced decrease of tumor growth 
rates was observed in patients put on bevacizumab therapy. Of note, however, we observed 
evidence for drug -induced tumor growth inhibition also for the other types of systemic 
therapies analyzed in our series, although to considerably smaller extent than for 
bevacizumab. The activity of bevacizumab or other anti-angiogenic agents targeting the 
vascular endothelial growth factor (VEGF) pathway in WHO II and III meningioma seems 
rational from a pathobiological point of view, as prominent expression of VEGF and its 
receptors as well as neo-angiogenesis have repeatedly been shown in this tumor type.20,21 
Ongoing prospective studies (NCT00972335, NCT01125046) will provide more data on the 
role of bevacizumab for aggressive meningiomas. A point of caution, however, may be 
deduced from our observation of increased growth rates after cessation of bevacizumab 
therapy that were not noted in patients treated with other drugs. “Rebound effects” 
characterized by more malignant behavior after termination of bevacizumab therapy have 
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been described for vestibular schwannoma and further studies should address this issue also in 
meningioma.22   
 
Bevacizumab has shown considerable and clinically relevant anti-edematous properties in 
gliomas and brain metastases. Our data indicate that this effect is also relevant in meningioma 
patients, as we saw shrinking of peritumoral edema volumes exclusively in patients under 
bevacizumab treatment. This finding is well in line with reports showing an important role for 
VEGF in edema formation in meningioma.23-25 Thus, bevacizumab treatment may be of 
particular clinical benefit in meningioma patients with symptomatic peritumoral edema and 
may help to decrease symptomatic burden and corticosteroid need.  
 
Our study has several limitations; despite the multicenter approach, we were able to assemble 
only a relatively small patient cohort in this rare tumor type. In a number of cases we were 
unfortunately not able to retrospectively retrieve the neuroimages (or only neuroimages of 
insufficient quality), because they were done at external institutions. To overcome the 
individual bias of heterogenic time periods between the MR follow up examinations at each 
center, growth rates, which were defined as maximum change in tumor diameter or tumor 
volume over a period of time, were used. Another limitation is the heterogeneity of 
administered treatments and the retrospective mode of data analysis. Overall, it is important to 
note that our analyses are strictly descriptive and need to be carefully interpreted and 
validated by larger, optimally prospective investigations. In general, the lack of reductions in 
tumor sizes seen with systemic agents suggests that response rate is not an optimal endpoint 
for clinical trials with medical therapies in meningiomas, but that progression-free survival 
times or the change in growth rates may be more appropriate end-points.  In any case, our 
study emphasizes the need for standardisation of imaging protocols and clinical management 
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algorithms in aggressive meningioma patients to overcome the wide variation in clinical 
practice. 
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Figure 1: Visualization of change gradients of tumor diameter (A), tumor volume (B) and 
peritumoral edema (C) before (continuous-lines), during (dashed-lines) and after (dotted-
lines) systemic therapy.  The slopes describe the direction (decrease or increase) and 
steepness (intensity) for the three groups respectively. A very steep line therefore indicates a 
rapid increase. As clearly visible growth velocity for all three measures (diameter growth rate, 
volume growth rate, edema change rate) degrades from before to after therapy. 
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Figure 2: Growth rates expressed as lesion diameter (A) or volume (B) shown for different 
systemic therapies (black lines = bevacizumab, blue lines = chemotherapy, green lines = 
somatostatin analogues, magenta lines = tyrosine kinase inhibitor) in the “therapeutic” and 
“post-therapeutic” period. Since the growth rate of lesion diameter after administration of 
tyrosine kinase inhibitor was zero, no magenta line is shown in this section. Column C 
represents the changes of peritumoral edema volumes shown for bevacizumab (black line) 
versus all chemotherapies, somatostatin analogues and tyrosine kinase inhibitors pooled (red 
line) during therapy application. The slopes describe the direction (decrease or increase) and 
steepness (intensity) for the three groups respectively. A very steep line therefore indicates a 
rapid increase. 
